Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Brain tissue and pathology

Topic: Amyloid, tau and blood-test diagnosis

Background The APOE epsilon4 allele is associated with the risk of late-onset Alzheimer's disease. The age at which memory decline diverges among persons who are homozygous for the APOE epsilon4 allele, those who are heterozygous for the allele, and noncarriers is unknown. Methods Using local advertisements, we recruited cognitively normal subjects between the ages of 21 and 97 years, who were grouped according to their APOE epsilon4 status.

Key findings

Why it matters

This longitudinal study followed cognitively normal subjects to determine when memory decline diverges among those with different APOE epsilon4 statuses. It found that the age at which memory decline diverges among homozygous carriers, heterozygous carriers, and noncarriers was previously unknown.

Study details

How this study scored 70/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 70 of 100.70 of 100 points earned30 not earned

Published in a top-tier journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (The New England journal of medicine)
Journal's citation record 4 / 4 New England Journal of Medicine: journal h-index 1,505 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2009 — within 20 year(s) of the newest study here
Sample size 2 / 4 815 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 530 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 27.9 citations a year over 19 year(s) since 2009
Impact for its field and year 4 / 6 Cited 18.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 30 other studies in this library
Still being cited 3 / 4 Cited 70 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Eric M. Reiman: h-index 151 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Arizona: institution h-index 1,336 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 19605830)
Free to read 0 / 2 Behind a paywall — scores zero
Total 70 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

APA 7th

Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., et al. (2009). Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. The New England journal of medicine. https://doi.org/10.1056/nejmoa0809437

Vancouver

Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. The New England journal of medicine. 2009. doi:10.1056/nejmoa0809437. PMID: 19605830.

BibTeX

@article{caselli2009-19605830,
  author  = {Caselli, R. J. and Dueck, A. C. and Osborne, D. and Sabbagh, M. N. and Connor, D. J. and Ahern, G. L. and Baxter, L. C. and Rapcsak, S. Z. and others},
  title   = {{Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect}},
  journal = {The New England journal of medicine},
  year    = {2009},
  doi     = {10.1056/nejmoa0809437},
  pmid    = {19605830},
  url     = {https://doi.org/10.1056/nejmoa0809437}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Later studies that cite this one

30 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Brain tissue and pathology

Also tagged “amyloid-beta”

1,339 studies in the library carry the topic tag “amyloid-beta”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →